MET and non-small cell lung carcinoma: Other ADCs being developed that may be promising in the future for MET-amplified EGFR-mutated NSCLC include ABBV-400, which targets c-MET and topoisomerase, in which there is an ongoing phase 1 study (NCT05029882) along with a biparatropic MET × MET ADC REGN-M114 (NCT04982224) (35, 36).